Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858833 | 0.86 | APEX1 (0.53) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL20856994 | 0.85 | PTGS1 (0.48) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL858563 | 0.85 | PTGS1 (0.48) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL13846143 | 0.84 | APEX1 (0.51) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL8214588 | 0.82 | KDM4E (0.38) | ALDH1A1MAPT | |
| SCHEMBL8209776 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL13868150 | 0.78 | PTGS1 (0.47) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL859188 | 0.78 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL858566 | 0.76 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2APEX1KMT2AMEN1 | |
| SCHEMBL859001 | 0.76 | PTGS1 (0.49) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | BIPAR SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | BIPAR SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | BIPAR SCIENCES, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | BIPAR SCIENCES, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | BIPAR SCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | BIPAR SCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2009064444-A2 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | BIPAR SCIENCES | 2009-05-21 | — | — | US | disclosed |
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | BIPAR SCIENCES | 2009-05-21 | — | — | US | disclosed |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES | 2009-05-14 | — | — | US | disclosed |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES | 2009-05-14 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008030883-A2 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | PARP2, PARP1, PARP3 | ALDH1A1 612/4885SMN1; SMN2 4035/4885APEX1 266/4885 |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | PARP2, PARP12, PARP3 | ALDH1A1 349/4885SMN1; SMN2 4051/4885APEX1 1052/4885 |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | PARP2, PARP1, PARP3 | ALDH1A1 543/4885SMN1; SMN2 4824/4885APEX1 369/4885 |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | PARP2, PARP12, PARP15 | ALDH1A1 484/4885SMN1; SMN2 4189/4885APEX1 1812/4885 |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | ERBB2, EGFR, ERBB3 | ALDH1A1 932/4885SMN1; SMN2 4816/4885APEX1 2818/4885 |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | IDH3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1 | ALDH1A1 154/4885SMN1; SMN2 2359/4885APEX1 752/4885 |
| US-20080103104-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | ALDH1A1 794/4885SMN1; SMN2 969/4885APEX1 157/4885 |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | TOP2B, TOP2A, TOP1 | ALDH1A1 1190/4885SMN1; SMN2 460/4885APEX1 2250/4885 |
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | ALDH1A1 794/4885SMN1; SMN2 969/4885APEX1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.